8,706 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Acquired by Bank of Montreal Can

Bank of Montreal Can purchased a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 8,706 shares of the medical instruments supplier’s stock, valued at approximately $1,650,000.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in ICU Medical by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 2,122,104 shares of the medical instruments supplier’s stock valued at $472,466,000 after buying an additional 171,851 shares during the last quarter. Wellington Management Group LLP grew its position in shares of ICU Medical by 71.6% in the first quarter. Wellington Management Group LLP now owns 1,516,089 shares of the medical instruments supplier’s stock valued at $337,542,000 after purchasing an additional 632,609 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of ICU Medical by 3.4% in the first quarter. JPMorgan Chase & Co. now owns 779,705 shares of the medical instruments supplier’s stock worth $128,620,000 after purchasing an additional 25,284 shares during the period. Morgan Stanley lifted its position in shares of ICU Medical by 233.5% during the 4th quarter. Morgan Stanley now owns 679,912 shares of the medical instruments supplier’s stock worth $107,073,000 after purchasing an additional 476,012 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in ICU Medical by 7.1% during the 2nd quarter. Victory Capital Management Inc. now owns 640,039 shares of the medical instruments supplier’s stock valued at $114,049,000 after purchasing an additional 42,162 shares during the period. Institutional investors own 91.49% of the company’s stock.

ICU Medical Stock Performance

ICUI opened at $81.08 on Friday. The stock has a market cap of $1.95 billion, a PE ratio of -69.30 and a beta of 0.69. ICU Medical, Inc. has a 1 year low of $80.21 and a 1 year high of $212.43. The stock’s 50 day simple moving average is $114.75 and its 200-day simple moving average is $153.57. The company has a current ratio of 2.63, a quick ratio of 0.97 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.15 by $0.43. The company had revenue of $549.31 million during the quarter, compared to analysts’ expectations of $562.90 million. ICU Medical had a negative net margin of 1.25% and a positive return on equity of 6.53%. Sell-side analysts forecast that ICU Medical, Inc. will post 5.18 EPS for the current year.

Insider Activity

In other ICU Medical news, COO Christian B. Voigtlander sold 6,850 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $129.04, for a total transaction of $883,924.00. Following the completion of the transaction, the chief operating officer now owns 13,603 shares in the company, valued at $1,755,331.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on ICUI. TheStreet downgraded shares of ICU Medical from a “c-” rating to a “d+” rating in a research note on Tuesday, October 10th. StockNews.com started coverage on shares of ICU Medical in a report on Thursday, October 5th. They set a “hold” rating on the stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.